The process of drug discovery and development has undergone a dramatic transformation over the last decade, driven by multiple forces coming from the pharmaceutical/biotechnology industries, government funding agencies, academic programs, and life sciences and diagnostics companies. There is now a mutually beneficial environment where more collaboration is possible between these entities that will accelerate innovations and improvements in the efficiency of developing therapeutics.
Under the leadership of D. Lansing Taylor, the Drug Discovery Institute at the University of Pittsburgh is optimizing the discovery and development of new molecular entities through collaborations among faculty members, academic centers, corporations, and government agencies, together with innovations in chemistry, molecular biophysics, and quantitative systems pharmacology.